Search

Your search keyword '"Mark A. Mintun"' showing total 102 results

Search Constraints

Start Over You searched for: Author "Mark A. Mintun" Remove constraint Author: "Mark A. Mintun" Publisher wiley Remove constraint Publisher: wiley
102 results on '"Mark A. Mintun"'

Search Results

1. Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease

3. Methods and future directions for evaluation of Tau PET signal

4. Reproducibility of applying multiple statistical analyses to data from the TRAILBLAZER‐ALZ clinical trial of donanemab in early symptomatic Alzheimer's disease

5. TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment

7. Neuropathological diagnoses of subjects autopsied in the phase 3 clinicopathological study of flortaucipir F18 PET imaging

8. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab

9. Network diffusion model enhances predictions of future tau‐PET burden in Alzheimer’s patients

10. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale

11. O5‐01‐06: EARLY TAU DETECTION AND IMPLICATIONS FOR DISEASE PROGRESSION

12. P4‐388: TRAILBLAZER‐ALZ (NCT03367403): A PHASE 2 DISEASE‐MODIFICATION COMBINATION THERAPY TRIAL TARGETING MULTIPLE MECHANISMS OF ACTION ALONG THE AMYLOID PATHWAY

13. O1‐09‐01: SIGNIFICANT AND SUSTAINED FLORBETAPIR F18 UPTAKE REDUCTION IN PATIENTS WITH SYMPTOMATIC ALZHEIMER'S DISEASE WITH LY3002813, A β‐AMYLOID PLAQUE‐SPECIFIC ANTIBODY

14. P3‐440: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD

15. IC‐P‐009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD

16. O3‐13‐02: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL

17. P4‐321: TAU PET IN A4: PRELIMINARY REPORT

18. IC‐P‐216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL

19. IC-P-162: RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM

20. O3-02-03: ASSOCIATION BETWEEN APOE ISOFORM AND 18-MONTH TAU ACCUMULATION

21. DT-01-05: TEMPORAL LOBE QUANTITATION OF FLORTAUCIPIR PET IMAGES MAY IMPROVE DETECTION OF INTERMEDIATE NEUROFIBRILLARY TANGLE PATHOLOGY IN AUTOPSY-VALIDATED CASES

22. [O5–01–01]: PET BIOMARKERS IN THE EXPEDITION 3 TRIAL OF PATIENTS WITH MILD AD

23. [IC‐P‐206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR

24. [P4–530]: MODELING OF TAU TRAJECTORIES ACROSS THE ALZHEIMER's DISEASE SPECTRUM USING [18F]‐FLORTAUCIPIR PET IMAGING

25. [O1–08–06]: AN UPDATE ON THE BINDING PROFILE OF FLORTAUCIPIR IN AD VERSUS NORMAL CNS PROTEINS AND NORMAL BRAIN

26. [P2–383]: COMPARISON OF REGIONAL FLORTAUCIPIR PET TO QUANTITATIVE TAU AND AMYLOID IMMUNOASSAY IN PATIENTS WITH ALZHEIMER's DISEASE PATHOLOGY: A PILOT CLINICO‐PATHOLOGICAL STUDY

27. [P4–235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR

28. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18 F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy

29. P3-322: RELATIONSHIPS BETWEEN FLORTAUCIPIR TAU BINDING AND REGIONAL BRAIN ATROPHY IN AMYLOID POSITIVE SUBJECTS ACROSS THE ALZHEIMER'S DISEASE SPECTRUM

30. P4-290: IMAGING BIOMARKER TRAJECTORIES OF THE MILD AD DEMENTIA POPULATION IN THE EXPEDITION3 TRIAL

31. P3-026: IMPLEMENTATION OF DUAL-PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE-AD CLINICAL TRIAL

32. IC-05-01: DEBATE: MRI VERSUS PET: WHICH IMAGING MODALITY PROVIDES THE BEST BIOMARKER AND FOR WHICH PURPOSE?

33. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

34. O1‐07‐02: Image Patterns and Clinical Phenotypes Associated with Fastest Increase of TAU Burden Measured by Longitudinal [18F]‐AV‐1451 (T807) PET Studies

35. IC‐P‐194: Image Patterns and Clinical Phenotypes Associated with Fastest Increase of TAU Burden Measured by Longitudinal [18F]‐Av‐1451 (T807) PET Studies

36. O4‐08‐06: SAFETY, PHARMACOKINETICS (PK), AND FLORBETAPIR F‐18 POSITRON EMISSION TOMOGRAPHY (PET) AFTER MULTIPLE DOSE ADMINISTRATION OF LY3002813, A β‐AMYLOID PLAQUE‐SPECIFIC ANTIBODY, IN ALZHEIMER’S DISEASE (AD)

37. O4‐07‐01: Evolution of [ 18 F]Av‐1451 Pet Tau Signal: Interim Analysis of an 18‐Month Phase 2 Study

38. IC‐P‐196: Quantification of TAU Load Using [ 18 F]AV‐1451 and PET

39. IC‐P‐022: Conversion of Amyloid Quantitation With Florbetapir Suvr to The Centiloid Scale

40. P3‐242: Conversion of Amyloid Quantitation with Florbetapir SUVR to the Centiloid Scale

41. O4‐02‐05: The Relationship of [18F]Av‐1451 Pet Tau Images to Changes in Cognition Over Time

42. P4‐215: Quantification of Tau Load Using [ 18 F]AV‐1451 and Pet

43. Amyloid deposition, hypometabolism, and longitudinal cognitive decline

44. Visinin-like protein-1: Diagnostic and prognostic biomarker in Alzheimer disease

45. Endogenous dopamine (DA) competes with the binding of a radiolabeled D3 receptor partial agonist in vivo: A positron emission tomography study

46. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults

47. [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: A selective radioligand for dopamine D3receptors. II. Quantitative analysis of dopamine D3and D2receptor density ratio in the caudate-putamen

48. [3H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D3receptors. I. In vitro characterization

49. Decreased cerebrospinal fluid Aβ42correlates with brain atrophy in cognitively normal elderly

Catalog

Books, media, physical & digital resources